Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (14199)	7/23/2000 2:38:26 AM
From: Cacaito	Read Replies (2) \| Respond to of 17367

Biogen, pIII psoriasis recruitment 500 patients completed for the IV preparation. A second 500 patient pIII for the Subcutaneous preparation expected to complete recruitment by the end of summer. End of the year results for both, FDA application early 2001, in the market early 2002. Of course, if Amevive works, but pII some 250 patients showed good results. Amevive is also after other autoimmune diseases and renal transplant market. Just keeping a check on the competition. Larry S post in Yahoo an Individual Investor article about xoma piper piping jaffrey, some timing goals about antiCd11a for psoriasis similar to Bgen's amevive, but no mentioned of how recruitment is ongoing. It seems both drugs are expected for early 2002. PDLI is at pII recruitment level.